Black Diamond Therapeutics (BDTX) Cash from Operations Growth (3y) (2022 - 2026)

Black Diamond Therapeutics (BDTX) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Black Diamond Therapeutics 99.59 Mn -18.67 Mn - 20.06%

Historic Data

Download Data
DateValue
Mar 31, 2026 20.06%
Dec 31, 2025 32.37%
Sep 30, 2025 21.90%
Jun 30, 2025 20.26%
Mar 31, 2025 56.97%
Dec 31, 2024 14.45%
Sep 30, 2024 24.66%
Jun 30, 2024 16.36%
Mar 31, 2024 4.65%
Dec 31, 2023 4.00%
Sep 30, 2023 -16.93%
Jun 30, 2023 -1.93%
Mar 31, 2023 -20.96%
Dec 31, 2022 -43.11%
Sep 30, 2022 -45.85%
Jun 30, 2022 -53.45%
Mar 31, 2022 -60.81%